259 related articles for article (PubMed ID: 26894870)
1. Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.
Molino NM; Neek M; Tucker JA; Nelson EL; Wang SW
Biomaterials; 2016 Apr; 86():83-91. PubMed ID: 26894870
[TBL] [Abstract][Full Text] [Related]
2. Multi-compartmental vaccine delivery system for enhanced immune response to gp100 peptide antigen in melanoma immunotherapy.
Kalariya M; Ganta S; Amiji M
Pharm Res; 2012 Dec; 29(12):3393-403. PubMed ID: 22806408
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.
Qiu Z; Huang H; Grenier JM; Perez OA; Smilowitz HM; Adler B; Khanna KM
Cancer Immunol Res; 2015 May; 3(5):536-46. PubMed ID: 25633711
[TBL] [Abstract][Full Text] [Related]
4. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.
Wang XY; Chen X; Manjili MH; Repasky E; Henderson R; Subjeck JR
Cancer Res; 2003 May; 63(10):2553-60. PubMed ID: 12750279
[TBL] [Abstract][Full Text] [Related]
5. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
7. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.
Molino NM; Anderson AK; Nelson EL; Wang SW
ACS Nano; 2013 Nov; 7(11):9743-52. PubMed ID: 24090491
[TBL] [Abstract][Full Text] [Related]
8. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity.
Neal ZC; Bates MK; Albertini MR; Herweijer H
Mol Ther; 2007 Feb; 15(2):422-30. PubMed ID: 17235322
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses.
Neek M; Tucker JA; Kim TI; Molino NM; Nelson EL; Wang SW
Biomaterials; 2018 Feb; 156():194-203. PubMed ID: 29202325
[TBL] [Abstract][Full Text] [Related]
10. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
[TBL] [Abstract][Full Text] [Related]
12. Systemically administered gp100 encoding DNA vaccine for melanoma using water-in-oil-in-water multiple emulsion delivery systems.
Kalariya M; Amiji MM
Int J Pharm; 2013 Sep; 453(2):400-7. PubMed ID: 23702000
[TBL] [Abstract][Full Text] [Related]
13. Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP100(25-33) peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma.
Chang X; Xia CQ
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):46-52. PubMed ID: 26545782
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.
Hamdy S; Molavi O; Ma Z; Haddadi A; Alshamsan A; Gobti Z; Elhasi S; Samuel J; Lavasanifar A
Vaccine; 2008 Sep; 26(39):5046-57. PubMed ID: 18680779
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles.
Kokate RA; Thamake SI; Chaudhary P; Mott B; Raut S; Vishwanatha JK; Jones HP
Nanomedicine (Lond); 2015; 10(6):915-29. PubMed ID: 25867857
[TBL] [Abstract][Full Text] [Related]
16. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax.
Mansour M; Pohajdak B; Kast WM; Fuentes-Ortega A; Korets-Smith E; Weir GM; Brown RG; Daftarian P
J Transl Med; 2007 Apr; 5():20. PubMed ID: 17451606
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
[TBL] [Abstract][Full Text] [Related]
18. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
19. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
[TBL] [Abstract][Full Text] [Related]
20. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
Mahnke K; Qian Y; Fondel S; Brueck J; Becker C; Enk AH
Cancer Res; 2005 Aug; 65(15):7007-12. PubMed ID: 16061687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
